Alnylam Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.71B | $2.25B | $1.83B | $1.04B | $844.3M | $492.9M | $219.8M | $74.9M |
| ONPATTRO | $172.8M | $252.9M | $354.5M | $557.6M | $474.7M | $306.1M | — | — |
| AMVUTTRA | $2.31B | $970.5M | $557.8M | $93.8M | $0 | $0 | — | — |
| GIVLAARI | $308.5M | $255.9M | $219.3M | $173.1M | $127.8M | $55.1M | — | — |
| OXLUMO | $191.4M | $167.1M | $109.8M | $69.8M | $59.6M | $333.0K | — | — |
| Collaboration and other revenue | $553.4M | $510.2M | $546.2M | $134.9M | $181.0M | $131.3M | — | — |
| Royalty revenue | $174.0M | $91.8M | $40.6M | $8.2M | $1.2M | $0 | — | — |
| Cost of Revenue | $677.2M | $306.5M | $268.2M | $140.2M | $115.0M | $74.2M | $25.1M | $1.8M |
| Gross Profit | $3.04B | $1.94B | $1.56B | $897.2M | $729.3M | $418.7M | $194.7M | $73.1M |
| Gross Margin | 81.8% | 86.4% | 85.3% | 86.5% | 86.4% | 84.9% | 88.6% | 97.6% |
| Operating Expenses | ||||||||
| Research & Development | $1.32B | $1.13B | $1.00B | $883.0M | $792.2M | $654.8M | $655.1M | $505.4M |
| SG&A Expense | $1.21B | $975.5M | $795.6M | $770.7M | $620.6M | $588.4M | $479.0M | $382.4M |
| Operating Income | $501.6M | $-176.9M | $-282.2M | $-785.1M | $-708.7M | $-828.4M | $-939.4M | $-814.7M |
| Operating Margin | 13.5% | -7.9% | -15.4% | -75.7% | -83.9% | -168.1% | -427.5% | -1,087.6% |
| Interest Expense | — | — | $121.2M | $156.0M | $143.0M | $84.5M | $0 | $0 |
| Pretax Income | $323.2M | $-377.4M | $-433.5M | $-1.13B | $-852.1M | $-855.6M | $-885.3M | $-760.7M |
| Income Tax Expense | $9.4M | $-99.2M | $6.7M | $4.2M | $680.0K | $2.7M | $863.0K | $823.0K |
| Net Income | $313.7M | $-278.2M | $-440.2M | $-1.13B | $-852.8M | $-858.3M | $-886.1M | $-761.5M |
| Net Margin | 8.4% | -12.4% | -24.1% | -109.0% | -101.0% | -174.1% | -403.2% | -1,016.6% |
| EPS (Basic) | $2.39 | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | $-7.57 |
| EPS (Diluted) | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 | $-7.46 | $-8.11 | $-7.57 |
| Shares Outstanding (Basic) | 131.0M | 127.7M | 124.9M | 121.7M | 118.5M | 115.0M | 109.3M | 101.2M |
| Shares Outstanding (Diluted) | 134.7M | 127.7M | 124.9M | 121.7M | 118.5M | 115.0M | 109.3M | 101.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |